Researchers at Baylor College of Medicine and collaborating institutions identified a vulnerability in acute myeloid leukemia that connects FLT3-targeted therapy to ferroptosis, according to a study published in Nature Cell Biology. The report links inhibiting mutant FLT3 proteins to induction of a second, highly destructive cell-death process beyond the direct kinase blockade. The finding suggests that combining or sequencing FLT3 inhibitors with strategies that further engage ferroptosis pathways could improve therapeutic depth, at least in the models tested. It also expands the mechanistic map of how targeted treatments can drive cell death through multiple parallel routes. For AML developers and translational teams, the work provides a concrete biology hook for biomarker and combination exploration—particularly in FLT3-mutant subtypes where resistance remains a central clinical challenge.